Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.6K
Benefits of Self-Esteem01:25

Benefits of Self-Esteem

190
Self-esteem—an individual's overall evaluation of their worth—plays a complex role in psychological functioning and well-being. It is often associated with many positive traits, such as confidence, optimism, and perseverance. Individuals with high self-esteem typically experience better sleep, manage peer pressure more effectively, and report greater life satisfaction. Conversely, low self-esteem has been consistently linked with increased risks of depression, anxiety, and poor...
190
Relative Risk01:12

Relative Risk

2.0K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One Block, Two Block, or More? Keep Counting.

Circulation·2026
Same author

A Narrow Window in a Wide Complex Rhythm.

Circulation·2026
Same author

QT Interval Correction in Left Bundle Branch Area Pacing.

JACC. Clinical electrophysiology·2025
Same author

Risks of Safety Mode in Recalled Boston Scientific Pacemakers: Implications for Pacemaker-Dependent Patients.

Journal of the American College of Cardiology·2025
Same author

All Implantable Cardioverter Defibrillators Are Not Programmed Equal: A Case Report of Pseudomalfunction.

A&A practice·2025
Same author

Insights Into Left Bundle Branch Area Pacing: Important Lessons Learned.

JACC. Clinical electrophysiology·2024

Related Experiment Video

Updated: Jan 21, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K

Antiarrhythmic Drugs: Risks and Benefits.

Pranav Mankad1, Gautham Kalahasty2

  • 1Department of Cardiology, Virginia Commonwealth University Health System, PO Box 980053, Richmond, VA 23235, USA.

The Medical Clinics of North America
|August 6, 2019
PubMed
Summary

Selecting antiarrhythmic drugs is challenging due to their narrow therapeutic window. Clinical factors and side-effect profiles are more critical than cellular mechanisms for effective drug selection and patient monitoring.

Keywords:
Antiarrhythmic therapyCardiac action potentialMechanisms of arrhythmiaPractical approach to antiarrhythmics

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.6K
Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
08:27

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Published on: September 27, 2019

7.2K

Related Experiment Videos

Last Updated: Jan 21, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.6K
Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
08:27

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Published on: September 27, 2019

7.2K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antiarrhythmic drugs are crucial for managing cardiac arrhythmias.
  • Their narrow therapeutic window presents significant clinical challenges.
  • Understanding drug mechanisms is complex and often insufficient for clinical practice.

Purpose of the Study:

  • To simplify the understanding of cellular mechanisms of antiarrhythmic drugs.
  • To provide a practical framework for selecting and using antiarrhythmic medications.
  • To emphasize the importance of clinical factors over cellular mechanisms in drug selection.

Main Methods:

  • Review of existing literature on antiarrhythmic drug mechanisms.
  • Analysis of clinical factors influencing antiarrhythmic drug selection.
  • Development of a simplified approach to antiarrhythmic drug therapy.

Main Results:

  • Cellular mechanisms are a preliminary consideration for antiarrhythmic drug selection.
  • Clinical factors, side-effect profiles, and proarrhythmic risks are paramount.
  • A simplified, practical approach enhances appropriate drug selection and monitoring.

Conclusions:

  • Effective antiarrhythmic drug therapy relies on integrating cellular knowledge with clinical practice.
  • Prioritizing patient-specific factors and risk assessment leads to safer and more effective treatment.
  • This approach aims to improve clinical outcomes for patients with cardiac arrhythmias.